Pan-Asian study for EGFR exon 20 insertion lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial is building a large database of lung cancer patients from Asia who have a specific EGFR mutation (exon 20 insertion). Your medical records and treatment information will be collected to help doctors learn more about this type of cancer and improve care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced non-small cell lung cancer (NSCLC).
- You tested positive for a specific EGFR mutation called 'exon 20 insertion'.
- You were diagnosed between January 2013 and December 2024.
- You are an adult (age as defined by your country's rules).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at real-world information from people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to understand how patients are treated and what outcomes they have, which may help improve future care.
This trial uses long-read sequencing to study the EGFR gene in women with EGFR-positive lung cancer. It aims to learn more about the cancer's DNA to improve future treatments.
This trial collects information from people with a specific type of advanced lung cancer to create a comparison group. It helps researchers understand how well new treatments work without giving any experimental medicine.
This study uses a blood test to look for signs of lung cancer in people who have never smoked or smoked very little. It focuses on Asian and Latinx communities because certain gene changes are more common in these groups.
This study looks at how EGFR-mutated lung cancer changes over time and tries to find markers that can predict how well you might respond to treatment. You will provide a tumor sample for genetic analysis.
This trial uses your tumor sample to guide personalized treatment decisions for certain lung cancers. It may help by matching you to a more targeted plan based on genetic testing and your prior treatment history.
Hear when a new Advanced EGFR Exon 20 Insertion Mutated Non-Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.